Inside Ownership

Very Brief Background History

In 1989,Professor Sir John Michael Brady mother-in-law dies from breast cancer. Professor Brady transitions to teaching medical imaging where he meets Dr Ralph Highnam. Together they laid out the basis for breast composition. In 2000s Dr Highnam, Professor Brady fellow scientists Professor Nico Karssemeijer and Professor Martin Yaffe began to make progress in the field and attract clinic interest. In 2009, Brady, Highnam, Karssemeijer and Yaffe met at a major medical imagine trade show in Chicago. They pool their talents and collective knowledge to create Volpara (Volumetric parameters).

Roger Allen is a current member of the board. He’s a entrepreneur and a venture capitalist he joined the board of Volpara back in 2010 and has the biggest inside ownership.

In April 2022, Dr Ralph Highnam steps down from CEO and transits to Chief Sciecne & Innovation Officer. Teri Thomas is appointed CEO.

Approx Inside Ownership End Dec 2022 – Percent of total shares issued. Value shares today using closing price of $0.52. 252,113,909

                                                                        Ordinary Shares          Percentage      Net Value

Roger Allen (Patagorang Pty LTd)                18,467,848 Shares       7.32%              $9.6m

Ralph Highnam                                               16,213,561 Shares      6.43%              $8.43m

Professor Sir John Michael Brady                   6,619,075 Shares        2.62%             $3.44m

Prof Martin Yaffe                                            2,066,483 Shares         0.82%             $1.07m

Prof Nico Karssemeijer                                   1,806,806 Shares        0.72%              $0.94m

John Diddams (Board)                                    1,172,295 Shares        0.46%              $0.61m

John Pavlidis (Board)                                      69,100 Shares             0.027%            $0.03m

Total                                                                46,415,168 Shares      18.41%            $24.14m

Volpara Insiders Buying 2022

John Pavlidis - Independent, Non-Executive Director

Buying 29 June 2022               69,100 shares average cost $0.41 per share ($28,609.61)    

John Diddams – Independent, Non-Executive Director (Retire since 2022 AGM)

22 June 2022   Buying             30,000 shares average cost $0.45 per share ($13,553.00)

16 June 2022   Buying             30,001 shares average cost $0.56 per share ($16,665.34)

At time of Retiring

Whitfield Investments Pty Ltd            1,060,768 Ordinary shares

Galdarn Pty Ltd                                   111,527 Ordinary shares

                                    Total                1,172,295

Paul Reid – Chair, Independent, Non-Executive Director

15 June 2022   Buying             115,000 shares average cost $0.5822 ($66,958.91)

Volpara History Capital Raises/Acquisitions

Volpara Capital Raise – Raised $132.7m since listing April 2016 Current market cap 133.6m at 0.53. 

·      April 2020 – Raises $37m, $28m Institutional, $9m Retail at $1.30 per share 

·      June 2019 – Raises $55m, $45m Institutional, $10m Retail at $1.50 per share

·      April 2018 – Raises $20m, $15m Institutional, $5.0 Retail at $0.60 per share

·      November 2016 – Raises $10.7m, $7m Institutional, $3.7m Retail at $0.60 per share

·      April 2016 -Raises $10m at IPO at $0.50 per share

Volpara Acquisitions

·      February 2021 – CRA Health US$18.0m with a further US$4.0m payable upon meeting key performance and staff retention targets – industry leader in breast cancer risk assessment spun out from Massachusetts General Hospital

https://www.asx.com.au/asxpdf/20210202/pdf/44s8m0v7qkrzm1.pdf

·      June 2019 – MRS Systems US$14.59m (~A$21.15m) – a medical software company that provides comprehensive patient track and communication and a radiology reporting platform, for sub-specialty radiology applications including breast and lung imaging.

https://www.asx.com.au/asxpdf/20190603/pdf/445k85khy2qchl.pdf